Semaglutide is described by EMA as a GLP-1 receptor agonist, tirzepatide acts on GLP-1 and GIP pathways, and retatrutide has been studied as a triple hormone receptor agonist. Read them as related, not interchangeable.
Semaglutide is described by EMA as a GLP-1 receptor agonist, tirzepatide acts on GLP-1 and GIP pathways, and retatrutide has been studied as a triple hormone receptor agonist. Read them as related, not interchangeable.
Educational content. Not medical advice and not a claim that Peptyds products diagnose, treat, cure, or prevent disease.
EMA describes Wegovy's active substance semaglutide as a GLP-1 receptor agonist.[1]
EMA describes tirzepatide, the active substance in Mounjaro, as acting in the same way as GLP-1 and glucose-dependent insulinotropic polypeptide, also called GIP.[2]
Retatrutide has been discussed in peer-reviewed phase 2 literature as a triple-hormone-receptor agonist involving GIP, GLP-1, and glucagon receptor activity.[3]
A systematic review can compare GLP-1 receptor agonists and polyagonists across trials, but buyers should still separate approved-medicine context from investigational research context.[4][1][2]
This article is educational and does not recommend a medication, dose, or treatment route.[5]
If you already know the molecule, go to the product page for quality and storage. If you know the goal, start with metabolic support.
A responsible GLP-1 hub should make it easy to compare mechanism context, evidence stage, batch testing, and shipping requirements without making personal medical recommendations.[6][7]
Keep the category clear: related molecules, different mechanisms, different evidence maturity.
No. They are related by incretin biology but differ in receptor activity and evidence context.[1][2][3]
This article treats retatrutide as an investigational research context based on the cited phase 2 literature, not as an approved medicine recommendation.[3]
No. It explains category context and quality questions. Medical decisions require a qualified healthcare professional.[5]